Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for MDD

January 29, 2016 10:03 am | News | Comments

Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for adjunctive treatment of Major Depressive Disorder (MDD). This follows the Fast Track Designation for rapastinel granted by the FDA in 2014. Read more...


FDA OKs Merck Hepatitis C Drug, Adding to Patient Choices

January 29, 2016 9:57 am | by Linda A. Johnson, AP Business Writer | News | Comments

Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck. Read more...


Drug Discovery Spotlight: Zika Virus 'Spreading Explosively;' Theranos Lab in 'Immediate Jeopardy;' Depression Screenings

January 29, 2016 9:27 am | by Stephanie Guzowski, Editor | News | Comments

Welcome to Drug Discovery Spotlight, where we’ve rounded up this week’s top news, trending headlines, and all-around interesting reads.


New Molecular Profiling for Glioma

January 29, 2016 8:35 am | by University of Sao Paulo | News | Comments

DNA methylation is a biochemical reaction frequently found in cancer cells that prevents the activation of the gene next to it. Read more...


Finding the Right Anti-Clotting Drug for You

January 29, 2016 8:30 am | by Kumamoto University | News | Comments

A new blood clotting analysis system designed in Japan makes it easier to determine the effects of taking one or more anti-clotting drugs. Read more...


U.S. Official Sees Zika Vaccine Trials Starting By End of 2016

January 29, 2016 8:22 am | by Julie Steenhuysen, Reuters | News | Comments

The United States has two potential candidates for a vaccine for the Zika virus and may begin clinical trials in people by the end of this year. Read more...


HBV Market Growth to 2024 Limited by Low Diagnosis and Treatment Rates

January 29, 2016 8:21 am | by Daian Cheng, Ph.D., Infectious Disease Analyst, GlobalData | News | Comments

This problem is exacerbated by the fact that there is no active universal screening program for chronic hepatitis B. Read more...


Faster Drug Discovery

January 29, 2016 8:21 am | by Rob Matheson, MIT News Office | News | Comments

The fast, low-cost assay allows for much larger experiments than previously possible, and for gene-expression profiling to be used much earlier in the drug-discovery process. Read more...


HIV Growing Resistant to Common Treatment

January 29, 2016 8:20 am | by Ryan Bushey, Associate Editor | News | Comments

New study suggests tenofovir became less effective over a period of time. Read more...


Opioid Prescribing for Chronic Pain — Achieving the Right Balance Through Education

January 28, 2016 12:32 pm | by Boston University | News | Comments

In recent decades, the United States has seen a dramatic increase in opioid prescribing for chronic pain. That growth has been associated with increasing misuse of these medications, leading to alarming increases in unintentional opioid overdose deaths. Read more..


Drug Provides Better Kidney Transplant Survival Rates Than Current Standard of Care

January 28, 2016 12:27 pm | by UC San Francisco | News | Comments

For the first time, an immunosuppressive agent has shown better organ survival in kidney transplant recipients than a calcineurin inhibitor, the current standard of care, according to a worldwide study led by UC San Francisco and Emory University investigators. Read more...


Antidepressant Use Doubles the Risk of Aggression, Suicide in Children

January 28, 2016 12:05 pm | by Stephanie Guzowski, Editor | News | Comments

Antidepressants’ side effects appear to be more severe for children and adolescents than previously reported in medical journals, with young people having a doubled risk of aggression and suicide when they take one of the five most commonly prescribed antidepressants, according to a new meta-analysis of 68 studies, published Wednesday in BMJ. Read more...


Long-Acting ADHD Drug Gets FDA Approval

January 28, 2016 11:42 am | by Ryan Bushey, Associate Editor | News | Comments

Adzenys XR-ODT is the first type of extended release tablet to gain U.S. approval for this disorder. Read more...


Ancient Clay Fights Antibiotic-Resistant Bacteria, Says Study

January 28, 2016 10:14 am | by Ryan Bushey, Associate Editor | News | Comments

The compound was able to kill 16 strains of the toughest drug-resistant microbes. Read more...


Boehringer Ingelheim's Gilotrif Demonstrated Superiority to Iressa in NSCLC

January 28, 2016 9:57 am | News | Comments

Boehringer Ingelheim announced today the results of the LUX-Lung 7 trial. Superiority in progression-free survival and time to treatment failure was demonstrated with second-generation EGFR-directed therapy afatinib versus first-generation gefitinib in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with common EGFR mutations. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.